Undeterred by domestic regulatory concerns, Hims & Hers is actively executing its global strategy. On December 10, the company launched its comprehensive weight-loss program in the United Kingdom, ...

The dramatic stock slump, which puts Novo Nordisk at a historically cheap valuation, reflects investor concern over future sales growth and competition, particularly from rival Eli Lilly & Co.

Eli Lilly and Company plans to invest more than $6 billion in a new manufacturing facility in Huntsville, Alabama.

Novo Nordisk enters the final stretch of 2025 looking almost unrecognizable from the market darling it was just months ago.

Detailed price information for Eli Lilly and Company (LLY-N) from The Globe and Mail including charting and trades.

Eli Lilly and Company announced it will invest more than $6 billion to build a major pharmaceutical manufacturing facility on ...

A perfect storm of clinical setbacks, intensifying competition, and internal upheaval has triggered a historic sell-off in ...

In a strategic pivot, the company has launched its weight-loss program in the United Kingdom. There, Hims & Hers is offering legitimate, branded medications—Novo Nordisk's Wegovy and Eli Lilly's ...

Once construction is complete in 2032, the company plans on creating some of its "biggest medicines" at the new facility.

Hims Hers Health Inc (NYSE:HIMS) stock fell 4.4% Wednesday after U.S. lawmakers introduced legislation that could ...

Eli Lilly plans API plant in Alabama to produce small molecule and peptide medicines, creating 450 jobs and enhancing U.S. pharmaceutical supply chains.

Eli Lilly, known for medications including Prozac, the weight loss drugs Mounjaro and Zepbound, and the mass producing ...